Introduction {#sec1-1}
============

Pityriasis lichenoides chronica (PLC) is a chronic papulosquamous disorder of unknown aetiology with remissions and exacerbations. Although being a self-limited condition, therapeutic approach is required based on cosmetic and symptomatic concerns. Many treatment options including topical or systemic corticosteroids, oral tetracycline, topical calcineurin inhibitors such as tacrolimus, and methotrexate have been used with different success rates. NB-UVB phototherapy has recently demonstrated high levels of efficacy and tolerability in the treatment of patients with PL. Despite the variety of reports in the literature, no studies have been conducted to primarily evaluate the efficacy of such modality in PLC case series treatment.

This prospective clinical study presents the experiences with NB-UVB monotherapy in the treatment of PLC on Vietnamese patients.

Methods {#sec1-2}
=======

Twenty-nine Vietnamese patients, aged 3 to 75 years old (11 males, 18 females, the initial mean age of disease 25 ± 16.8 years old) were treated with NB-UVB mono-therapy. Treatment with NB-UVB (311 nm) was given three times weekly in a Daavlin cabinet (Daavlin, CA, USA) equipped with Philips TL-01/100 W fluorescent lamps (Philips Company, Eindhoven, the Netherlands). The initial and increasing treatment dose of NB-UVB in every treatment session depended on patients' skin type classified by Fitzpatrick (AAD-2010 guidelines). In the case of mild side-effects including mild to moderate erythema, burning sensation, the dose of NB-UVB was decreased by 20%. In case of severe side-effects such as severe erythema, burning or photosensitivity, the treatment was stopped, and the patient was applied topical corticosteroids with an oral non-steroidal anti-inflammatory drug (NSAID). If one to three sessions were missed, the dose was unchanged, and if more than four sessions were missed, the dose was decreased by 25% (within 7 sessions), 50% (from 8 to 11 sessions) or began again (over 12 sessions).

Complete response (CR) was defined as more than 90% resolution in skin lesions (papulosquamous and plaque lesions). Partial response (PR) was defined as the resolution of 50-90% in skin lesions. Poor response (NR) was taken as less than 50% reduction in lesions. Patients were assessed every 6 sessions until they cleared skin lesions or after completed 36 sessions. If the patient's skin lesions cleared before completing 36 treatment sessions, they were observed for at least 3 months to determine any recurrence. Detection of more than 10 new lesions was defined as recurrence.

Both thickness and scaling scores were assessed at the initial and at the end of treatment (PASI score). Patients also fulfilled a self-evaluation satisfaction questionnaire.

Results {#sec1-3}
=======

After one month treatment (4.6 weeks), 82.8% complete response was achieved with the mean number of treatment sessions was 13.8 (range: 4-30 sessions). The mean number of sessions required to achieve the first clinical response was 6.4 (range: 3-14 sessions).

Most patients had reduced the total body surface area (BSA) after 6 sessions (p \< 0.001). The improvement of skin had seen and maintained after 12 sessions (p \< 0.001) as shown in [Figure 1](#F1){ref-type="fig"}.
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Thickness, scale and pruritus of skin lesions had good improvement after the last session by NB-UVB mono-therapy (p \< 0.001) as shown in [Figure 2](#F2){ref-type="fig"}.
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The mean cumulative dose was 9760.5 mJ/cm^2^. All patients have remained relapse-free for at least 3 months.

A group of 27/29 patients treated with phototherapy reported minimal erythema (69%) and itchy (55.2%). These side effects have resolved quickly after topical emollients and irradiation dose reduction. None of the patients discontinued treatment as a result of side effects.

All patients were satisfied with the treatment; more than 80% of the patients would recommend the procedure.

Discussion {#sec1-4}
==========

In National Hospital of Dermatology and Venereology (NHDV), 29 patients with PLC (11 males and 18 females) with the initial mean age of disease was 25 ± 16,8 years and mean disease duration was 39,9 ± 57,9 months. This is convenient with criteria chronic and most commonly occurs in children and young adults of PLC. Responses to various treatment modalities, such as topical corticosteroids and oral antibiotics were extremely poor despite diffuse skin lesions. Topical corticosteroids are unable to affect the course of disease whereas systemic antibiotics, including erythromycin and tetracycline, have been used for their anti-inflammatory rather than antibiotic effects \[[@ref1]\], \[[@ref2]\].

The exact mechanism of NB-UVB for a phototherapeutic treatment modality for PL, including PLC is unknown. In the previous studies, NB-UVB has been shown to be the safe and effective treatment option for several inflammatory and neoplastic skin diseases characterised by epithelial and dermal infiltrates rich in T lymphocytes. In chronic plaque psoriasis, NB-UVB mono-therapy could reduce the number of activated T cells by inducing T cells apoptosis \[[@ref3]\]. Recent studies have revealed that UVB suppresses the all activating and antigen-presenting capacity of epidermal Langerhans cells and therefore UVB modulates the circulating cytokines accounts, such as IL-1, IL-6, IL-8, IL-12 and TNF-α production by human keratinocytes due to immunosuppression \[[@ref4]\]. The expression of ICAM-1 has been suppressed in cultured human keratinocytes, and decreases the release of histamine from mast cells by systemic UVB-induced, in turn, decrease the itch response of skin lesions \[[@ref5]\]. In the present study, 29 PLC patients were treated with NB-UVB monotherapy. 82.8% of patients achieved a CR within 13.8 ± 7.4 sessions (4, 6 weeks) of their first therapy session. Thickness, scale and pruritus of skin lesions were reported reducing after finished treatment. No patients relapsed during the follow-up (for at least 3 months after the last treatment). These results, compared with the published data, demonstrated that NB-UVB therapy should be highly recommended for PLC treatment.

Similarly, several studies demonstrated the efficacy of NB-UVB phototherapy in PLC treatment. Farnaghi et al. described their experience with NB-UVB in eight PLC patients. CR was achieved by 87.5% (7/8) of the patients within a mean number of 37 ± 11 treatments \[[@ref6]\]. Fernandez at al. has reported on 8 adults diffuse PLC patients whose disease showed no response to topical therapy. A CR rate of 88% in a mean of 23 sessions (cumulative dose 16,99 J/cm^2^) was obtained \[[@ref7]\]. Ersoy et al. reported on 25 PLC patients (14 male, 11 female). CR was achieved in 48% of the patients after 25 sessions (8 weeks) of the median number treatment \[[@ref8]\]. Although the relapse-free rates after NB-UVB monotherapy varied from 42 to 73% in the literature, the discrepancy in relapse rates between previous studies and the present study may reflex differences both in the length of follow-up periods and in the choice of the initial and increasing dose in every session treatment. In the current study, NB-UVB phototherapy proved to be safe modality in the treatment of PLC patients. Short-term adverse effects showed minimal erythema and itch in most patients which could be quickly resolved while long-term adverse effects were unavailable.

In conclusion, NB-UVB therapy is an effective and safe option for the treatment and management of PLC. It also has several advantages over treatment with BB-UVB and PUVA. So NB-UVB should be considered as the first line in generalised cases interested in treatment.

**Funding:** This research did not receive any financial support

**Competing Interests:** The authors have declared that no competing interests exist
